Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. BLS Pharmaceuticals's current 1-Year Share Buyback Ratio was -8.60%.
ASX:BLS's 1-Year Share Buyback Ratio is ranked better than 58.13% of 1113
companies
in the Biotechnology industry
Industry Median: -13.6
vs ASX:BLS: -8.60
BLS Pharmaceuticals (ASX:BLS) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
BLS Pharmaceuticals 1-Year Share Buyback Ratio Related Terms
ASX:BLS vs KHC, GIS: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, BLS Pharmaceuticals's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -8.60 mean?
BLS Pharmaceuticals (ASX:BLS) has a 1-Year Share Buyback Ratio of -8.60 as of Dec. 2025. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for BLS Pharmaceuticals and its competitors. According to the industry distribution chart, BLS Pharmaceuticals ranks #466 out of 1113 companies in the Biotechnology industry, placing it in the top 41.9%.
Is BLS Pharmaceuticals' 1-Year Share Buyback Ratio too high?
BLS Pharmaceuticals' current 1-Year Share Buyback Ratio is -8.60. Based on the distribution chart, BLS Pharmaceuticals ranks #466 out of 1113 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' 1-Year Share Buyback Ratio compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #466 out of 1113 companies for 1-Year Share Buyback Ratio. This puts BLS Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for BLS Pharmaceuticals and its competitors. BLS Pharmaceuticals's current 1-Year Share Buyback Ratio is -8.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.70, compared to a current price of A$0.87 — trading 23.6% above its estimated fair value. The current 1-Year Share Buyback Ratio is -8.60. BLS Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current 1-Year Share Buyback Ratio is -8.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.87 is trading 23.6% above its estimated GF Value™ of A$0.70.
GuruFocus considers BLS Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:BLS:
1-Year Share Buyback Ratio: -8.60
GF Value™: A$0.70 vs. price of A$0.87 (23.6% above fair value)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
44GF Score
Get the complete analysis for ASX:BLS
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
